- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Marksans Pharma Limited — Board Meeting, 05-02-2026: Outcome of Board Meeting
05-02-2026 | 01:36 pm
05-02-2026 | 01:36 pm
Marksans Pharma board approved Q3 & 9M results. Consolidated revenue rose to ₹785.28 Cr (vs ₹681.85 Cr LY) with PAT at ₹113.63 Cr (vs ₹105.51 Cr LY). EPS hit ₹2.50. Notably, new subsidiaries were launched in Ireland and Canada, hinting at global expansion.
No comments yet. Be the first to comment!